Sun Pharma Gets US FDA Approval for ILUMYA to Treat Psoriatic Arthritis
"The US FDA approval is based on Phase 3 clinical data from the INSPIRE-1 and INSPIRE-2 studies, which evaluated ILUMYA's safety and efficacy in patients with active psoriatic arthritis."
ILUMYA Receives Approval for Active Psoriatic Arthritis
The approval follows the FDA's acceptance of Sun Pharma's supplemental Biologics License Application (sBLA) for ILUMYA. The drug is an IL-23 inhibitor administered by a healthcare professional.
ILUMYA was earlier approved in the US in 2018 for adults with moderate-to-severe plaque psoriasis. The latest approval expands its use to adults with active psoriatic arthritis, a condition that causes joint inflammation and is associated with psoriasis.
Key Details of the FDA Approval
- Approved indication: Treatment of adults with active psoriatic arthritis
- Drug: ILUMYA (tildrakizumab-asmn)
- Regulatory approval: US FDA approval of the supplemental Biologics License Application
- Drug category: IL-23 inhibitor
- Administration: Given by a healthcare provider
- Clinical evidence: Supported by the Phase 3 INSPIRE-1 and INSPIRE-2 studies
- Safety findings: The company reported that no new safety signals were identified in the Phase 3 studies
- Earlier approval: ILUMYA received US approval in 2018 for moderate-to-severe plaque psoriasis
What to Watch Next
The expanded approval could support Sun Pharma's presence in the US immunology market. Investors will watch how the company develops ILUMYA's presence in the psoriatic arthritis segment and whether the new indication contributes to future product sales.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Natco Pharma Promoters and Promoter Group Acquire 22.11 Lakh Shares Through Rights Issue
Natco Pharma Limited’s promoters and promoter group entities have acquired 22,11,776 equity shares through the company’s Rights Issue. The shares were allotted on October 26, 2026, at Rs 750 per share, taking the total value of acquisition to about Rs. 165.88 crore. The company’s paid up equity share capital increased to 19,61,67,952 equity shares following the Rights Issue.
Jio Financial Services Allots 25 Crore Shares to Promoter Group Entities
Jio Financial Services Limited has allotted 25 crore equity shares to two promoter group entities following the conversion of preferential warrants. The allotment was made at Rs.316.50 per share, including a face value of Rs.10 and a premium of Rs.306.50 per share.
Ginni Filaments: SBICAP Trustee Releases Encumbrance on 26.48 Lakh Shares
SBICAP Trustee Company Limited has disclosed the release of encumbrance on 26,48,300 equity shares of Ginni Filaments Limited under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The released shares represent 3.09% of the total voting share capital of Ginni Filaments. Following the transaction dated October 29, 2026, SBICAP Trustee's encumbered shareholding declined from 1,04,08,300 equity shares (12.15%) to 77,60,000 equity shares (9.06%). The transaction was executed by SBICAP Trustee Company Limited in its capacity as a Security Trustee. The entity does not belong to the promoter or promoter group of Ginni Filaments.